Antiphospholipid Syndrome During Pregnancy | omega academix Learning Club

Background

Antiphospholipid syndrome (APS) is an autoimmune thrombophilic disorder defined by characteristic clinical events together with persistent antiphospholipid antibodies. In pregnancy, the syndrome is associated with recurrent miscarriage, fetal loss, pre-eclampsia, placental insufficiency, fetal growth restriction, premature delivery, and maternal arterial or venous thrombosis. Antibodies may activate endothelial cells, monocytes, and platelets, increase tissue factor and thromboxane A2, interfere with anticoagulant pathways, and activate complement. [1]

Pregnancy itself increases thrombotic tendency through venous stasis, endothelial changes, and physiologic shifts in coagulation. APS adds a “second hit” that may promote placental thrombosis, impaired trophoblast function, fetal loss, or maternal venous thromboembolism. The review emphasizes coordinated preconception, obstetric, and medical care rather than antibody positivity alone as a basis for diagnosis or treatment. [1]

Review Snapshot

Review type	Narrative state-of-the-art review	Literature window	2006–2011; PubMed and Cochrane
Core condition	Primary or secondary APS; aPL-positive states	Pregnancy focus	Fetal loss, pre-eclampsia, IUGR, VTE
Diagnostic panel	LA, anticardiolipin, anti-β2GPI	Management focus	Low-dose aspirin plus heparin

Key Findings — Diagnosis

APS classification requires at least one clinical criterion and one laboratory criterion; antibody positivity alone does not establish APS.
Clinical criteria include documented arterial, venous, or small-vessel thrombosis, or defined pregnancy morbidity: fetal death at or beyond 10 weeks, premature birth before 34 weeks due to severe pre-eclampsia/eclampsia or placental insufficiency, or three consecutive unexplained abortions before 10 weeks.
Laboratory criteria include lupus anticoagulant, medium/high-titer anticardiolipin IgG/IgM, or anti-β2-glycoprotein I IgG/IgM, each confirmed on at least two occasions 12 weeks apart.
When APS is suspected, a panel is preferred because individual tests may be negative. Routine screening of healthy pregnant women is not indicated; testing is directed toward thrombotic or pregnancy complications and selected patients with systemic lupus erythematosus.

Key Findings — Pregnancy Risk

Recurrent miscarriage is the most characteristic obstetric manifestation. The review reports that approximately 10–15% of women with recurrent miscarriage may have APS, while women with high-titer IgG anticardiolipin antibodies and prior fetal loss may have a markedly elevated risk of another loss. Other reported complications include pre-eclampsia/eclampsia, HELLP syndrome, oligohydramnios, prematurity, intrauterine growth restriction, placental insufficiency, and fetal or neonatal thrombosis. Evidence linking aPL to preterm birth and growth restriction was described as heterogeneous and sometimes conflicting.

Management and Thromboprophylaxis

Clinical context	Approach discussed in review	Monitoring emphasis	Key caution
APS with recurrent pregnancy loss	Low-dose aspirin plus heparin	Frequent prenatal care; fetal growth and placental surveillance	Individualize dose and timing
Prior thrombosis	Anticoagulation strategy with specialist care	Assess thrombosis symptoms throughout pregnancy and postpartum	Higher-risk pathway
Uncomplicated APS	Preconception counseling and coordinated care	Ultrasound at 30–32 weeks; earlier if indicated	Avoid applying old review recommendations uncritically

Why This Matters for Practice

The review’s central message is that APS pregnancy care should combine accurate classification, repeated antibody confirmation, preconception counseling, and close maternal–fetal surveillance. It describes heparin as the anticoagulant of choice during pregnancy because it does not cross the placenta, and notes practical advantages of low-molecular-weight heparin over unfractionated heparin, including more predictable pharmacokinetics and lower risks of heparin-induced thrombocytopenia and osteoporosis. The review cites evidence and guidelines favoring low-dose aspirin combined with low-dose heparin or low-molecular-weight heparin for recurrent miscarriage associated with APS, while acknowledging historical trial controversy.

Takeaway

APS is diagnosed by the combination of clinical morbidity and persistent laboratory abnormalities—not by a single positive antibody test. In pregnancy, the highest-value actions are appropriate testing, risk stratification, preconception planning, coordinated obstetric–hematology care, and surveillance for thrombosis, pre-eclampsia, placental insufficiency, and impaired fetal growth. Because the source review was published in 2011, its treatment recommendations should be checked against current professional guidelines before clinical use.

Reference

[1] Di Prima FAF, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E, De Domenico R, Monte S. Antiphospholipid Syndrome during pregnancy: the state of the art. Journal of Prenatal Medicine. 2011;5(2):41–53. Source: attached article PDF.